

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/033,571-Conf. #9714 **INFORMATION DISCLOSURE** December 27, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Shuyuan Zhang 1648 Art Unit (Use as many sheets as necessary) Examiner Name M. Mosher 29853/37702 Attorney Docket Number Sheet . 1 of

			U.S. PA	TENT DOCUMENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
BB	A1	US-2002/0018723-A1	02-14-2002	Mera et al.		
	A2	US-2002/0045160-A1	04-18-2002	Carrion et al.		
	A3	US-4,797,368	01-10-1989	Carter et al.		
	A4	US-5,106,841	04-21-1992	Scheer		
	A5	US-5,139,941	08-18-1992	Muzyczka et al.		
	A6	US-5,552,309	09-03-1996	March		
	A7	US-5,670,488	09-23-1997	Gregory et al.		
	A8	US-5,733,720	03-31-1998	Olivo	,	
	A9	US-5,789,244	08-04-1998	Heidrun et al.		
	A10	US-5,824,544	10-20-1998	Armentano et al.		
	A11	US-5,932,210	08-03-1999	Gregory	1	
	A12	US-5,965,358	10-12-1999	Carrion et al.		
	A13	US-6,143,290	11-07-2000	Zhang et al.		
	A14	US-6,143,548	11-07-2000	O'Riordan, et al.		
	A15	US-6,168,944	01-02-2001	Condon et al.	· · · · · · · · · · · · · · · · · · ·	
	A16	US-6,194,191	02-27-2001	Zhang et al.		
		US-6,194,210	02-27-2001	Leu et al.		
	A18	US-6,261,823	07-17-2001	Tang et al.	·	
	A19	US-6,316,185	11-13-2001	Saifer, et al.		
	A20	US-6,383,795 .	05-07-2002	Carrion et al.		
	A21	US-6,447,995	09-10-2002	Carrion et al.		
	A22	US-6,586,226-A1	07-01-2003	Carrion et al.		
		US-6,689,600	02-10-2004	Wu et al.		
	A24	US-6,726,904-A1	04-27-2004	Krauss et al.		
	A25	US-60/026,667	09-25-1996	Guillaume et al.		
	A26	US-60/082,628	04-22-1998	Carrion et al.		
BB	A27	US-7,125,706-A1	10-24-2006	Zhang et al.		

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	1
BB	B1	JP-1279843	11-10-1989	Moritsugu Yasuo		
	B2	EP-0273085	07-06-1988	Battelle Memorial Institute		
	В3	WO-93/18790	09-30-1993	Csatary Laszlo		
	B4	WO-95/10601	04-20-1995	Viagene, Inc.		
	B5	WO-95/19427	07-20-1995	Genetic Therapy, Inc.		
	B6	WO-96/32116	10-17-1996	Inhale Therapeutic Systems		
	B7	WO-98/22588	05-28-1998	Introgen Therapeutics, Inc.		
	B8	WO-98/26048	06-18-1998	Schering Corp.		
	B9	WO-98/35554	08-20-1998	Canji, Inc.		
	B10	WO-99/12568	03-18-1999	Merch & Co., Inc.		
	B11	WO-99/41416	08-19-1999	Schering Corp.		
BB	B12	WO-99/43843	09-02-1999	Univ. Johns Hopkins Med.		

	Examiner Signature	/Benjamin Blumel/	Date Considered	01/30/2007	
--	-----------------------	-------------------	--------------------	------------	--

. Arricalities

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	stitute for form 1449/PT	· · · · · · · · · · · · · · · · · · ·		Complete if Known		
9003	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Application Number	10/033,571-Conf. #9714	
IN	FORMATIO	DN DI	SCLOSURE	Filing Date	December 27, 2001	
S	TATEMENT	ΓBY /	APPLICANT	First Named Inventor	Shuyuan Zhang	
				Art Unit	1648	
	(Use as many	sheets as	necessary)	Examiner Name	M. Mosher	
heet	2	of	7	Attorney Docket Number	29853/37702	

BB	B13	WO-99/54441	10-28-1999	Genvec, Inc.	,	
	B14	WO-00/32754	06-08-2000	Introgen Therapeutics, Inc.		
	B15	WO-00/34444	06-15-2000	Genvec, Inc.		
	B16	WO-00/40702	07-13-2000	Genvec, Inc.		
BB	B17	WO-02/29388	04-11-2002	Genvec, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uispto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
вв	C1	Arap et al., "Replacement of the p16/CDKN2 gene suppresses human glioma cell growth," Cancer Res., 55:1351-1354, 1995.	
	C2	Baichwal and Sugden, <i>In:</i> Kucherlapati R, ed. Gene Transfer. New York: Plenum Press, pp. 117-148, 1986.	
	СЗ	Batra et al., "IkappaBalpha gene transfer is cytoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death," <i>Am. J. Respir. Cell Mol. Biol.</i> , 21:238-245, 1999.	
	C4	Benvenisty and Neshif, "Direction introduction of genes into rats and expression of the genes," <i>Proc. Nat'l Acad. Sci. USA</i> , 83:9551-9555, 1986.	
	C5	Blackwell et al., "Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma," Arch. Otolaryngol Head Neck Surg., 125:856-863, 1999.	
	C6	Bussemakers et al., "Decreased expression of E-cadherin in the progression of rat prostatic cancer," Cancer Res., 52:2916-2922, 1992.	
	C7 ·	Butman et al., "High sensibitivity HPLC method for determining viral particle concentration," Presentation, 2000.	
	C8	Caldas et al., "Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma," Nat. Genet., 8:27-32, 1994.	
BB	C9	Carrion et al., "Intrinsic fluorescence of adenovirus type S: A sensitive detection alternative," Molecular Ther., 3:438, 2001.	
	C10	Cartwright, "Fermenter design for animal cell cultures," Animal Cells as Bioreactors, Cambridge University Press, 58-63, 1994.	
ВВ	C11	Carver et al., "Transgenic livenstock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep," <i>Biotechnology NY</i> , 11:1263-1270, 1993.	
	C12	Casey et al., "Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene," Oncogene, 6:1791-1797, 1991.	
	C13	Chen and Okayama, "High-efficiency transfection of mammalian cells by plasmid DNA," Mol. Cell Biol., 7:2745-2752, 1987.	
	C14	Cheng et al., "p16 Alterations and deletion mapping of 9p21-p22 in malignant mesothelioma," Cancer Res., 54:5547-5551, 1994.	
	C15	Cheung et al., "Cell-CAM105 isoforms with different adhesion functions are coexpressed in adult rat tissues and during liver development," <i>J. Biol. Chem.</i> , 268:6139-6146, 1993.	
BB	C16	Cheung et al., "Structure and function of C-CAM1," J. Biol. Chem., 268(32):24303-24310,	-1

Examiner		Date	01 /20 /0007
Signature	/Benjamin_Blumel/	Considered	01/30/2007

	Under the Paperwork Re	eduction Act	of 1995, no persons are require	U.S. Patent and Trader	PTO/SB/08A/B (09-06) oved for use through 03/31/2007. OMB 0651-0031 nark Office; U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number
Substitute for form 1449/PTO					Complete if Known
Substitute for form 1449/F 10				Application Number	10/033,571-Conf. #9714
11	FORMATIC	ON DI	SCLOSURE	Filing Date	December 27, 2001
			APPLICANT	First Named Inventor	Shuyuan Zhang
Ŭ	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1648
	(Use as many sheets as necessary)			Examiner Name	M. Mosher
Sheet	3	of	7	Attorney Docket Number	29853/37702

		l	1993.	
E	BB	C17	Cheung et al., "the cytoplaxmic domain of C-CAM is required for C-CAM-mediated adhesion function: studies of a C-CAM transcript containing an unspliced intron," <i>Biochem. J.</i> , 295:427-435, 1993.	
		C18	Chillon et al., "Group D adenoviruses infect primary central nervous system cells more efficiently than those from Group C," <i>J. Virol.</i> , 73:2537-2540, 1990.	
		C19	Chroboczek et al., "The sequence of the genome of adenovirus Type 5 and its comparison with the genome of adenovirus Type 2," <i>Virology</i> , 186:280-285, 1992.	
		C20	Coffin, "Retroviridae and their application," <i>In: Virology</i> , Fields et al. (eds.), New York: Raven Press, pp. 1437-1500, 1990.	
		C21	Corveleyn and Remon, "Maltodextrins as lyoprotectants in the lyophilization of a model protein, LDH," <i>Pharm. Res.</i> , 13:146-150, 1996.	
	•	C22	Coupar et al., "A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes," Gene, 68:1-10, 1988.	
	*. T	C23	Cristiano et al., "Viral and nonviral gene delivery vectors for cancer gene therapy," Cancer Detect Prev., 22:445-454, 1998.	
(A.			Croyle et al., "Factors that influence stability of recombinant adenoviral preparations for human gene therapy," <i>Pharm. Dev. Technol</i> , 3(3):373-383, 1998.	
		C25	Declaration of Peter Clark, Ph.D.: submitted in European Patent Application No. 97950677.1.	
		C26	Dorai et al., "A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells," <i>Int. J. Cancer</i> , 82:846-852, 1999.	
		C27	Dubensky et al., "Direct transfection of viral and plasmid DNA into the liver or spleen of mice," <i>Proc. Nat. Acad. Sci. USA</i> , 81:7529-7533, 1984.	
		C28	Edelman and Crossin, "Cell adhesion molecules: implications for a molecular histology," Annu. Rev. Biochem., 60:155-190, 1991.	
		C29	Edelman, "Cell adhesion and the molecular processes of morphogenesis," <i>Annu. Rev. Biochem.</i> , 54:135-169, 1985.	
		C30	Fechheimer et al., "Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading," <i>Proc. Nat. Acad. Sci. USA</i> , 84:8463-8467, 1987.	
		C31	Feldman et al., "Perspectives of arterial gene therapy for the prevention of restenosis," Cardiovasc. Res., 32:194-204, 1996.	
		C32	Ferkol et al., "Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer," FASEB J., 7:1081-1091, 1993.	
		C33	Fraley et al., "Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer," <i>Proc. Nat. Acad. Sci. USA</i> , 76:3348-3352, 1979.	
		C34	Freshney, "Animal Cell Culture: a Practical Approach," Second Edition, Oxford/New York, IRL Press, Oxford University Press, 1992.	
		C35	Fried and Bromberg, "Factors that affect the stability of protein-DNA complexes during gel electrophoresis," <i>Electrophoresis</i> , 18:6-11, 1997.	
		C36	Frixen et al., "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells," J. Cell Biol., 113:173-185, 1991.	
		C37	Ghosh and Bachhawat, In: Liver Disease, Targeted Diagnosis and Therapy using Specific Receptors and Ligands, Wu G, Wu C (eds.), Marcel Dekker, New York, pp. 87-104, 1991.	
		C38	Giancotti and Ruoslahti, "Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells," <i>Cell</i> , 60:849-859, 1990.	
BI	3_	C39	Gopal, "Gene transfer method for transient gene expression, stable transfection, and	

tall grafe of

The state of the s

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTC)		Complete if Known		
300	3311010 101111 144011 10			Application Number	10/033,571-Conf. #9714	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	December 27, 2001	
	TATEMENT			First Named Inventor	Shuyuan Zhang	
		- ; -	``	Art Unit	1648	
	(Use as many s	sheets as	necessary)	Examiner Name	M. Mosher	
Sheet	. 4	of	7	Attorney Docket Number	29853/37702	

	\Box		cotransfection of suspension cell cultures," Mol. Cell Biol., 5:1188-1190, 1985.	
		C40	Graham and Prevec, "Methods for construction of adenovirus vectors," Mol. Biotechnol.,	
_			3:207-220, 1995.	
В:	В	C41	Graham and Van Der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," Virology, 52:456-467, 1973.	
		C42	Hall et al., "Stabilizing effect of sucrose against irreversible denaturation of rabbit muscle lactate dehydrogenase," <i>Biophys. Chem.</i> , 57:47-54, 1995.	
		C43	Harland and Weintraub, "Translation of mammalian mRNA injected into Xenopus ooctyes is specifically inhibited by antisense RNA," <i>J. Cell Biol.</i> , 101:1094-1099, 1985.	
		C44	Herman et al., "The effect of bulking agent on the solid-state stability of freeze-dried methylprednisolone sodium succinate," <i>Pharm. Res.</i> , 11:1467-1473, 1994.	;
	.2	C45	Hermens and Verhaagen, "Viral vectors, tools for gene transfer in the nervous system," Prog. Neurbiol., 55:399-432, 1998.	į i
	.;	C46	Hermonat and Muzyscka, "Use of adenoassociated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells," <i>Proc. Nat. Acad. Sci. USA</i> , 81:6466-6470, 1984.	
. :		C47·	Hollstein et al., "p53 mutations in human cancers," Science, 253:49-53, 1991.	
	. !	C48	Hurwitz et al., "Suicide gene therapy for treatment of retinoblastoma in a murine model," Human Gene Therapy, 10:441-448, 1999:	
		C49	Hussussian et al., "Germline p16 mutations in familial melanoma," Nature Genetics, 8(1):15-21, 1994.	
		C50	Irie et al., "Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer;" Antisense Nucleic Acid Drug Dev., 9:341-349, 1999.	
		C51	Ishibashi et al., "Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery," <i>J. Clin. Invest.</i> , 92:883-893, 1993.	
		C52	Jardon and Garnier, "PH, pCO2, and temperature effect on R-adenovirus production," Biotechnol. Prog., 19:202-208, 2003.	•
		C53 .	Jiang et al., "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," <i>Proc. Nat. Acad. Sci. USA</i> , 93:9160-9165, 1996.	
		C54	July 17, 2006: Minutes of Oral Proceedings Before the Examining Division with decision to grant European Patent Application No. 97950677.1.	
	Ì	C55	Kamb et al., "A cell cycle regulator potentially involved in genesisi of many tumor types," Science, 264:436-440, 1994.	
		C56	Kamb et al., "Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus," <i>Nature Genetics</i> , 8:22-26, 1994.	
		C57	Kaneda et al., "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," Science, 243:375-378, 1989.	
		C58	Kato et al., "Expression of hepatitis b virus surface antigen in adult rat liver," J. Biol. Chem., 266:3361-3364, 1991.	
		C59	Klein et al., "High-velocity microprojectiles for delivering nucleic acids into living cells," <i>Nature</i> , 327:70-73, 1987.	
丁		C60	Kotani et al., "Improved methods of retroviral vector transduction and production for gene therapy," Human Gene Therapy, 5:19-28, 1994.	
		C61	Kraft et al., "Cell cycle-dependent multiplications of avian adenovirus in chicken embryo fibroblasts," <i>Archives of Virology</i> , 57:243-254, 1978.	
		C62	Lesch, "Gene transfer to the brain: emerging therapeutic strategy in psychiatry?," Biol. Psychiatry, 45:247-253, 1999.	
BE	3	C63	Lin and Guidotti, "Cloning and expression of a cDNA coding for a rat liver plasma membrane	

Examiner /1	Benjamin Blumel/	Date Considered	01/30/2007
-------------	------------------	--------------------	------------

Profession (2.4)

the August 1. Defre on August 1.

PTO/SB/08A/B (09-08)
Approved for use through 03/31/2007. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449/PTO			Complete if Known		
•				Application Number	10/033,571-Conf. #9714	
IN.	IFORMATIO	N DI	SCLOSURE	Filing Date	December 27, 2001	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Shuyuan Zhang	
_			•	Art Unit	1648	
	(Use as many sheets as necessary)			Examiner Name	M. Mosher	
Sheet	5	of	7 .	Attorney Docket Number	29853/37702	

		ecto-ATpase," J. Biol. Chem., 264:14408-14414, 1989.	
BE	C64	Lu et al., "Coat protein interactions involved in tobacco mosaic tobamovirus cross-protection," Virology, 248:188-198, 1998.	
	C65	Lueckel et al., "Formulations of sugars with amino acids or mannitol-influence of concentration ratio on the properties of the freeze-concentrate and the lyophilizate," <i>Pharm. Dev. Technol.</i> , 3:326-336, 1998.	
	C66	Marienfeld et al., "Autoreplication of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes," <i>Gene Ther.</i> , 6:1101-1113, 1999.	
	C67	Matsuura et al., "Altered expression of e-cadherin in gastric cancer tissues and carcinomatous fluid," <i>Brit. J. Cancer</i> , 66:1122-1130, 1992.	
	C68	Mercer, "Cell cycle regulation and the p53 tumor suppressor protein," Critic. Rev. Eukar. Gene Express, 2:251-263, 1992. Mincheff et al., "Naked DNA and adenoviral immunizations for immunotherapy of prostate	
	C69	cancer: a phase I/II clinical trial," Eur. Urol., 38:208-217, 2000.	
	C70	Mori et al., "Frequent somatic mutation of the MTSI/CDK4I (Multiple Tumor suppressor/Cyclin dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma," Cancer Res., 54:3396-3397, 1994.	
ľ	C71	Morrison et al., "Complete DNA sequence of canine adenovirus type 1," J. Gen. Virol., 78:873-878, 1997.	
	C72	Murakami et al., "Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye," <i>Analytical Biochemisty</i> , 274:283-288, 1999.	
	C73	Murphy et al., "Virus taxonomy, in B.N. Fields et al. (ed.), Fields Virology, 3rd edition Philadelphia: Lippencott-Raven Publishers: Table 6, pp.51-54, 1996.	
	C74	Nicolau and Sene, "Liposome-mediated DNA transfer in eukaryotic cells," <i>Biochem. Biophys. Acta</i> , 721:185-190, 1982.	
	C75	Nicolau et al., "Liposomes as carriers for in vivo gene transfer and expression," Methods Enzymol., 149:157-176, 1987.	
	C76	Nobori et al., "Deletions for the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers," Nature, 368:753-756, 1994.	
	C77	Obrink, "C-CAM (cell-CAM 105) - a member of the growing immunogloublin superfamily of cell adhesion proteins," <i>BioEssays</i> , 13:227-233, 1991.	
	C78	Odin and Obrink, "Quantitative determination of the organ distribution of the cell adhesion molecule cell-CAM 105 by radioimmunoassy," Exp. Cell Res., 171:1-15, 1987.	
	C79	Okamoto et al., "Mutations and altered expression of p16lNK4 in human cancer," <i>Proc. Nat. Acad. Sci. USA</i> , 91:11045-11049, 1994.	
	C80	Orlow et al., "Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors," Cancer Res., 54:2848-2851, 1994.	
	C81	Parks et al., "A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging," <i>J. Virol.</i> , 71:3293-3298, 1997.	
	C82	Paskind et al., "Dependence of moloney murine leukemia virus production on cell growth," Virology, 67:242-248, 1975.	
	C83	Perales et al., "Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake," <i>Proc. Nat. Acad. Sci. USA</i> , 91:4086-4090, 1994.	
	C84	Petrof, "Respiratory muscles as a target for adenovirus-mediated gene therapy," Eur. Respir. J., 11:492-497, 1998.	
BB	C85	Potter et al., "Enhancer-dependent expression of human k immunoglobullin genes introduced into mouse pre-B lymphocytes by electroporation," <i>Proc. Nat. Acad. Sci. USA</i> , 81:7161-7165, 1984.	

I / Renjamin Billine! /	Date Considered	01/30/2007
-------------------------	--------------------	------------

e session de la companya de la compa

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449/PT	0		Complete if Known		
000		•		Application Number	10/033,571-Conf. #9714	
IN	IFORMATIC	ON DISC	LOSURE	Filing Date	December 27, 2001	
S	TATEMENT	BY AP	PLICANT	First Named Inventor	Shuyuan Zhang	
_		_ ;		Art Unit	1648	
	(Use as many sheets as necessary)			Examiner Name	M. Mosher	
Sheet	6	of	7	Attorney Docket Number	29853/37702	

BB	C86	Racher et al., "Culture of 293 cells in different culture systems: cell growth and recombinant adenovirus production," <i>Biotechnology Techniques</i> , 9:169-174, 1995.				
	C87	Reddy et al., "Nucleotide sequence and transcription map of porcine adenovirus type 3," Virology, 251:414-426, 1998.				
	C88	Renan, "Cancer genes: current status, future prospects, and applications in radiotherapy/oncology," Radiother. Oncol., 19:197-218, 1990.				
	C89	Ridgeway, "Mammalian expression vectors," In: Rodriguez RL, Denhardt DT, ed. Vectors: A survey of molecular cloning vectors and their uses. Stoneham: Butterworth, pp.467-492, 1988.		•		
. : :	C90	Rippe et al., "DNA-mediated gene transfer into adult rat hepatocytes in primary culture," Mol. Cell Biol., 10:689-695, 1990.		1 37		
	C91	Robbins and Ghivizzani, "Viral vectors for gene therapy," Pharmacol. Ther., 80:35-47, 1998.		Shin as		
	C92	Robbins et al., "Viral vectors for gene therapy," Trends Biotechnol., 16:35-40, 1998.		5.75 TASK 1/2		
	C93	Sagrera et al., "Study of the influence of salt concentration on Newcastle disease virus matrix protein aggregation," <i>Biochem. Mol. Biol. Int.</i> , 46:429-435, 1998.		n nervision de la companya de la com		
	C94	Serrano et al., "A new regulatory motif in cell-cycle control causing specific hybition of cyclin D/CDK4," <i>Nature</i> , 366:704-707, 1993.		10 10 10 10 10 10 10 10 10 10 10 10 10 1		
	C95	Serrano et al., "Inhibition of ras-induced proliferation and cellular transformation by p16INK4," Science, 267:249-252, 1995.		i ing ing Light		
	C96	Shabram et al., "Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles," Human Gene Therapy, 8:453-465; 1997.		e in in		
	C97	Stewart et al., "Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial," <i>Gene Ther.</i> , 6:350-363, 1999.				
	C98	Takahasi et al., "Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions," Cancer Res., 52:2340-2342, 1992.				
	C99	Tur-Kaspa et al., "Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes," <i>Mol. Cell Biol.</i> , 6:716-718, 1986.				
	C100	Umbas et al., "Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer," Cancer Res., 52:5104-5109, 1992.				
	C101	Vanderkwaak and Alvarez, "Immune directed therapy for ovarian carcinoma," Curr. Opin. Obstet. Gynecol., 11:29-34, 1999.		•		
	C102	Vanlandschoot et al., "pH-dependent aggregation and secretion of soluble monomeric influenza hemagglutinin," <i>Arch. Virol.</i> , 143:227-239, 1998.				
	C103	Vossen and Fried, "Sequestration stabilizes lac repressor-DNA complexes during gel electrophoresis," <i>Anal. Biochem.</i> , 245:85-92, 1997.				
	C104	Wagner et al., "Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines," <i>Science</i> , 260:1510-1513, 1990.				
	C105					
	C106	Watt et al., "Human prostate-specific antigen: structural and functional similarity with serine proteases," <i>Proc. Nat. Acad. Sci. USA</i> , 83(2):3166-3170, 1986.				
	C107	Weinberg, "Tumor suppressor genes," Science, 254:1138-1145, 1991.				
	C108	Wilson, "Vehicles for gene therapy," Nature, 365:691-692, 1993.				
	C109	Wilson, "When bad gene transfer is good," J. Clin. Invest., 98:2435, 1996.				
	C110					
BB	C111	Wu and Wu, "Evidence for targeted gene delivery to HepG2 hepatoma cells in vitro," Biochemistry, 27:887-892, 1988.				
xamine		/Benjamin Blumel/ Date Considered 01/30/2007				

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	e for form 1449/P1	TO		Complete if Known		
0000				Application Number	10/033,571-Conf. #9714	
INFO	ORMATIC	ON DI	SCLOSURE	Filing Date	December 27, 2001	
STA	STATEMENT BY APPLICANT			First Named Inventor	Shuyuan Zhang	
				Art Unit	1648	
	(Use as many sheets as necessary)			Examiner Name	M. Mosher	
heel	7	of	7	Attorney Docket Number	29853/37702	

ВВ	C112	Wu and Wu, "Liver-directed gene delivery," Adv. Drug Delivery Rev., 12:159-167, 1993.	
ВВ		Wu and Wu, "Receptor mediated <i>in vitro</i> gene transfections by a soluble DNA courier system," J. Biol. Chem., 262:4429-4432, 1987.	
BB		Yang et al., "In vitro gene transfer to mammalian somatic cells by particle bombardment," Proc. Nat. Acad. Sci. USA, 87:9568-9572, 1990.	
BB	C115	Yotnda et al., "Efficient infection of primitive hematopoietic stem cells by modified adenovirus," Gene Ther., 8:930/937, 2001.	
ВВ	C116	Zheng et al., "Transcription units of E1a, E1b and pIX regions of bovine adenovirus type 3," <i>J. Gen. Virol.</i> , 80:1735-1742, 1999.	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Frank Bro Marker and

^{*}Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/	B/PTO	•	Complete if Known		
			•	Application Number	10/033,571-Conf. #9714	
INF	ORMATI	ON DI	SCLOSURE	Filing Date	December 27, 2001	
STATEMENT BY APPLICANT				First Named Inventor	Shuyuan Zhang	
				Art Unit	1648	
(Use as many sheets as necessary)			necessary)	Examiner Name	M. Mosher	
Sheet	1	of	1	Attorney Docket Number	29853/37702	

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where				
Initials*	No.1	Number-Kind Code ² (if known)	141.00.10004	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳٥				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BB		COTE et al., "Study of Adenovirus Production in Serum-Free 293SF Suspension Culture by GFP-Expression Monitoring" <i>Biotechnol. Prog.</i> , 1997, 13, 709-714, Biotechnology Research Institute, National Research Council Canada, 6100 Royalmount Avenue, Montreal, Quebec, Canada H4P 2R2, S8756-7938(97)00110-0 CCC, 1997 American Chemical Society and American Institute of Chemical Engineers	
BB		MASSIE et al., "Improved Adenovirus Vector Provides Herpes Simplex Virus Ribonucleotide Reductase R1 and R2 Subunits Very Efficiently" <i>Biotechnology</i> , Vol. 13; 602-608, June 1995, Institute of Research in Biotechnology, Montreal, Quebec, Canada H4P 2R2; Institute of Cancer of Montreal, Quebec, Canada H2I 4MI, 1995 Nature Publishing Group	
BB		ZHANG et al., "Adenovirus Inhibition of Cell Translation Facilitates Release of Virus Particles and Enhances Degradation of the Cytokeratin Network", <i>Journal of Virology</i> , Apr. 1994, p. 2544-2555, 00022-538X/94,1994 American Society for Microbiology, Department of Biochemistry and Kaplan Cancer Center, New York University School of Medicine, New York, New York 10016	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Benjamin Blumel/	Date	01/22/2007
Signature	/ 5 on j canon 5 a canon /	Considered	01/22/2007

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.